At what age should routine screening mammography be discontinued for a 40‑year‑old woman with average risk?

Screening Mammography Discontinuation Age

For a 40-year-old average-risk woman, screening mammography should continue as long as she remains in good health with a life expectancy of at least 10 years—there is no specific upper age cutoff, but decisions beyond age 75 should be based on health status and longevity rather than age alone. 1, 2

Key Principles for Discontinuation

The most recent and highest-quality evidence emphasizes that age alone should never be the sole criterion for stopping mammography screening. 1, 2 The decision framework is algorithmic:

Decision Algorithm for Screening Discontinuation:

Ages 40-74 years:

• Continue regular screening (annually or biennially depending on guideline followed)
• No consideration of stopping based on age

Age 75+ years:

• Assess overall health status
• Estimate life expectancy using validated mortality indices incorporating:
  • Age
  • Comorbidities
  • Functional status
• If life expectancy ≥10 years AND good overall health: Continue screening 1, 3
• If life expectancy <10 years OR poor health: Discontinue screening

At any age:

• Patient must be willing to undergo examination and subsequent testing/biopsy if abnormality detected 2

Evidence Supporting Continued Screening in Older Women

Although randomized controlled trials did not enroll women >74 years, observational studies demonstrate that women ≥75 years continue to benefit from screening mammography. 2 The 2025 ACR Appropriateness Criteria explicitly states there is no upper age limit agreed upon for screening mammography. 2

The rationale is straightforward: mortality reduction from screening mammography requires years to be fully realized, making life expectancy and competing comorbidities—not chronological age—the determining factors. 2

Guideline Variations

Different organizations frame this similarly but with slight nuances:

• ACR (2025): No upper age limit; continue if good health and willing to undergo follow-up 2
• ACS (2015-2019): Continue as long as overall health is good and life expectancy ≥10 years 1, 3, 4
• ACOG/ACP (2019): Beyond age 75, use shared decision-making informed by health status and longevity 1
• CTFPHC (2019): Recommends screening through ages 70-74 only (more conservative) 1

Common Pitfalls to Avoid

1. Don't use arbitrary age cutoffs (e.g., automatically stopping at 75 or 80)
2. Don't continue screening in women with <10 year life expectancy due to severe comorbidities—this leads to overdiagnosis without mortality benefit
3. Don't forget to assess patient willingness to undergo potential biopsies and treatment
4. Use validated tools (not clinical gestalt alone) to estimate life expectancy in older women

For Your 40-Year-Old Patient

This patient is decades away from any consideration of discontinuation. She should begin annual screening now (per ACR/NCCN) or at age 45 (per ACS), and continue indefinitely until her health status or life expectancy changes the risk-benefit calculation—likely not for 35+ years.